Lazard Asset Management
SRPT icon

Lazard Asset Management’s Sarepta Therapeutics SRPT Stock Holding History

Lazard Asset Management’s Portfolio SRPT Stock Details SRPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-25,000
Closed -$538K – 2073
2025
Q4 		$538K Sell
25,000
-12,500
-33% -$263K ﹤0.01% 1359
2025
Q3 		$723K Buy
+37,500
New +$669K ﹤0.01% 1244

Other funds holding SRPT

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
First Trust Advisors
First Trust Advisors Wheaton, Illinois $140B AUM 27.84% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
EAM
Erste Asset Management Vienna, Austria $10.8B AUM 38.54% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Lazard Asset Management's SRPT Position: Q3 2025 in Review

Lazard Asset Management sold out of Sarepta Therapeutics (SRPT) in Q3 2025, closing a stake of 445 shares — an estimated $7.93K sold.

Lazard Asset Management first reported a position in SRPT in Q2 2018 and held it in 27 quarters. The position peaked at $5.06M in Q4 2020. 319 funds tracked by Wall St. Rank hold SRPT as of Q3 2025.

  • Lazard Asset Management reported no remaining Sarepta Therapeutics position as of Q3 2025 after selling out during the quarter.
  • Lazard Asset Management sold 445 Sarepta Therapeutics shares in Q3 2025, an estimated $7.93K.
  • Lazard Asset Management first reported a position in Sarepta Therapeutics in Q2 2018 and held it in 27 quarters.
  • Lazard Asset Management's Sarepta Therapeutics position peaked at $5.06M in Q4 2020.
  • 319 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q3 2025.

Based on Lazard Asset Management's 13F filing for Q3 2025, filed 14 Nov 2025.